Answers are grounded in this paper and cite their sources.
This editorial discusses the implications of the 4D-ACS trial regarding DAPT de-escalation to low-dose prasugrel monotherapy in East Asian patients with ACS.
The 4D-ACS trial evaluates a strategy of shorter dual antiplatelet therapy followed by low-dose prasugrel monotherapy in East Asian patients with acute coronary syndromes undergoing percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Cuisset et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: